Related Experiment Video
Updated: May 16, 2026

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Perioperative B-blockers in non-cardiac surgery: actual situation
Ioanna Koniari1, George Hahalis
1Cardiology Department, University Hospital of Patras, Patras, Greece. iokoniari@yahoo.gr
Insights
Perioperative beta-blockade significantly reduces cardiac events like myocardial infarction in high-risk surgery patients. However, its benefit is uncertain for intermediate-risk patients or those with extensive preoperative ischemia.
Area of Science:
- Cardiology
- Anesthesiology
- Perioperative Medicine
Background:
- Cardiac events, including myocardial ischemia and infarction, are significant risks in non-cardiac surgery.
- Coronary artery disease patients face heightened mortality and morbidity from perioperative cardiac complications.
- Perioperative beta-blockade is investigated for its potential to mitigate these risks.
Purpose of the Study:
- To evaluate the impact of perioperative beta-blocker administration on cardiovascular events.
- To synthesize evidence from multiple randomized trials and meta-analyses.
- To clarify the efficacy of beta-blockers based on patient risk stratification.
Main Methods:
- Review of seven multicentre randomized trials (e.g., POISE, DECREASE, BBSA).
- Analysis of five meta-analyses examining perioperative beta-blocker use.
- Stratification of patient populations by clinical risk factors and preoperative ischemia levels.
Main Results:
- Meta-analyses show a significant reduction in myocardial ischemia and infarction with beta-blockers.
- Consistent evidence supports reduced cardiac mortality and myocardial infarction in high-risk patients undergoing surgery.
- No reduction in cardiac complications observed in patients without clinical risk factors.
Conclusions:
- Perioperative beta-blockade is effective for high-risk non-cardiac surgery patients with clinical risk factors.
- Patients with extensive preoperative ischemia remain at high risk despite beta-blocker therapy.
- The role of beta-blockers in intermediate-risk patients requires further investigation.
Abstract:
Cardiac events occur in 1% to 5% of patients undergoing non-cardiac surgery. Myocardial ischemia and nonfatal myocardial infarction constitute the most significant risk factors for mortality and cardiovascular morbidity, in patients with coronary artery disease. Perioperative b- blockade has been reported to reduce the risk of perioperative cardiac complications. Seven multicentre randomized trials have evaluated the impact of perioperative b-blocker administration on incidence of cardiovascular events.The Study of Perioperative Ischemia Research Group, the DECREASE and the BBSA trials focused on high risk patients for perioperative complications. The POBBLE, MaVS, and DIPOM trials did not target at patients with specific clinical risk factors, except DIPOM that included patients with diabetes. Finally, the POISE trial randomized patients with a wide variety of risk factors for perioperative cardiac complications. Interestingly, five meta-analyses reported a significant reduction in patients receiving b-blockers, with respect to perioperative myocardial ischemia and myocardial infarction. In conclusion, consistent evidence demonstrated a reduction in cardiac mortality and myocardial infarction by perioperative b-blockade in patients with clinical risk factors, undergoing high-risk non-cardiac surgery. However, patients with extensive preoperative ischemia were at high risk of perioperative cardiac complications, despite b-blocker therapy. Conversely, perioperative b-blocker therapy did not reduce the incidence of cardiac complications in patients without clinical risk factors. While, the safety and effectiveness of perioperative b-blockers in intermediate-risk patients, still remain a debatable issue.
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Cardiomyopathy VII: Pre and Post Operative Nursing Management
